We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

QNCX Quince Therapeutics Inc

-0.04 (-4.0%)
Dec 08 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 48,047
Bid Price 0.9425
Ask Price 0.96
News (1)
Day High 1.0195


52 Week Range


Day Low 0.96
Share Name Share Symbol Market Stock Type
Quince Therapeutics Inc QNCX NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-0.04 -4.0% 0.96 18:55:06
Open Price Low Price High Price Close Price Previous Close
1.00 0.96 1.0195 0.965 1.00
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
291 48,047 US$ 0.9773218 US$ 46,957 - 0.5401 - 1.93
Last Trade Type Quantity Price Currency
15:56:04 formt 100 US$ 0.96 USD

Quince Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
83.59M 42.87M - 0 -51.66M -1.21 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Quince Therapeutics News

Date Time Source News Article
12/08/202315:06Edgar (US Regulatory)Form 8-K - Current report
12/07/202317:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
12/01/202312:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/26/202316:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/24/202318:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of..
10/24/202318:34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of..
10/23/202315:05Edgar (US Regulatory)Form 8-K - Current report
10/23/202306:00Business WireQuince Therapeutics Completes Acquisition of EryDel S.p.A.
9/28/202315:53Dow Jones NewsQuince Therapeutics to Advance Study of EryDex as FDA Lifts..
9/28/202315:05Business WireU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s..
9/06/202306:18Edgar (US Regulatory)Form 8-K - Current report
9/06/202306:00Business WireQuince Therapeutics Appoints Dr. Charles S. Ryan as..
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No QNCX Message Board. Create One! See More Posts on QNCX Message Board See More Message Board Posts

Historical QNCX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.911.03620.910.9804297111,2340.055.49%
1 Month0.94251.03620.840.929995390,6640.01751.86%
3 Months1.251.310.841.0594,125-0.29-23.2%
6 Months1.511.700.841.21189,730-0.55-36.42%
1 Year0.661.930.54011.22713,0980.3045.45%
3 Years40.11121.980.540112.57644,565-39.15-97.61%
5 Years20.00121.980.540115.48462,930-19.04-95.2%

Quince Therapeutics Description

Quince Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on advancing precision therapeutics designed to precisely deliver small molecules, peptides, and large molecules directly to the site of bone diseases to promote more rapid healing with fewer off-target safety concerns. Quince Therapeutics serves customers in the United States.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |